[HTML][HTML] Mapping of crowdsourcing in health: systematic review
P Créquit, G Mansouri, M Benchoufi, A Vivot… - Journal of medical …, 2018 - jmir.org
Background Crowdsourcing involves obtaining ideas, needed services, or content by
soliciting Web-based contributions from a crowd. The 4 types of crowdsourced tasks (problem …
soliciting Web-based contributions from a crowd. The 4 types of crowdsourced tasks (problem …
[HTML][HTML] Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015
A Vivot, J Jacot, JD Zeitoun, P Ravaud, P Crequit… - Annals of …, 2017 - Elsevier
Background Prices of anti-cancer drugs are skyrocking. We aimed to assess the clinical
benefit of new drugs for treating advanced solid tumors at the time of their approval by the US …
benefit of new drugs for treating advanced solid tumors at the time of their approval by the US …
Jump, hop, or skip: modeling practice effects in studies of determinants of cognitive change in older adults
A Vivot, MC Power, MM Glymour… - American journal of …, 2016 - academic.oup.com
Improvements in cognitive test scores upon repeated assessment due to practice effects (PEs)
are well documented, but there is no empirical evidence on whether alternative …
are well documented, but there is no empirical evidence on whether alternative …
Using an Alzheimer disease polygenic risk score to predict memory decline in black and white Americans over 14 years of follow-up
Evidence on whether genetic predictors of Alzheimer disease (AD) also predict memory decline
is inconsistent, and limited data are available for African ancestry populations. For 8253 …
is inconsistent, and limited data are available for African ancestry populations. For 8253 …
Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: a single-centre cohort study on 114 patients
Objectives To assess efficacy and safety of rituximab (RTX) induction and maintenance
therapy for granulomatosis with polyangiitis (GPA) in a single-centre cohort study. Methods All …
therapy for granulomatosis with polyangiitis (GPA) in a single-centre cohort study. Methods All …
[HTML][HTML] Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004–2012
P Morlat, A Vivot, MA Vandenhende, FA Dauchy… - PLoS …, 2013 - journals.plos.org
Objective To examine the role of antiretroviral drugs (ART), HIV-related and traditional risk
factors on the incidence of chronic kidney disease (CKD) in HIV-infected patients. Design …
factors on the incidence of chronic kidney disease (CKD) in HIV-infected patients. Design …
[HTML][HTML] Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs
A Vivot, I Boutron, P Ravaud, R Porcher - Genetics in Medicine, 2015 - nature.com
Purpose: The aim of this study was to compare guidance for genetic testing in US Food and
Drug Administration (FDA)-approved drug labels in oncology to those of drugs for other …
Drug Administration (FDA)-approved drug labels in oncology to those of drugs for other …
Accuracy of repeated measurements of late‐night salivary cortisol to screen for early‐stage recurrence of C ushing's disease following pituitary surgery
…, J Asselineau, P Perez, A Vivot… - Clinical …, 2015 - Wiley Online Library
Objective The performance of late‐night salivary cortisol ( LNSC ) to accurately screen for
postoperative recurrence of Cushing's disease ( CD ) at an early stage is unknown. The aim of …
postoperative recurrence of Cushing's disease ( CD ) at an early stage is unknown. The aim of …
[HTML][HTML] Evidence for treatment-by-biomarker interaction for FDA-approved oncology drugs with required pharmacogenomic biomarker testing
A Vivot, I Boutron, G Béraud-Chaulet, JD Zeitoun… - Scientific reports, 2017 - nature.com
For oncology drugs that were approved by the US Food and Drug Administration (FDA) and
required pharmacogenomic biomarker testing, we describe 1) the use of enrichment (…
required pharmacogenomic biomarker testing, we describe 1) the use of enrichment (…
CD20 antigen may be expressed by reactive or lymphomatous cells of transformed mycosis fungoides: diagnostic and prognostic impact
ML Jullié, M Carlotti, A Vivot Jr… - The American journal …, 2013 - journals.lww.com
Mycosis fungoides (MF), the most common primitive cutaneous T-cell lymphoma, can undergo
transformation in about 10% of cases. Transformed mycosis fungoides (T-MF) is often …
transformation in about 10% of cases. Transformed mycosis fungoides (T-MF) is often …